Allogene Therapeutics
ALLO
ALLO
154 hedge funds and large institutions have $413M invested in Allogene Therapeutics in 2023 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 67 increasing their positions, 37 reducing their positions, and 29 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding in top 10
Funds holding in top 10: →
less funds holding
Funds holding: →
less ownership
Funds ownership: →
38% less capital invested
Capital invested by funds: $663M → $413M (-$250M)
55% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 29
58% less call options, than puts
Call options by funds: $195K | Put options by funds: $469K
Holders
154
Holding in Top 10
2
Calls
$195K
Puts
$469K
Top Buyers
| 1 | +$9.78M | |
| 2 | +$2.46M | |
| 3 | +$1.73M | |
| 4 |
BlackRock
New York
|
+$1.42M |
| 5 |
CANY
Caxton Associates (New York)
New York
|
+$1.3M |
Top Sellers
| 1 | -$9.27M | |
| 2 | -$7.84M | |
| 3 | -$2.97M | |
| 4 |
Two Sigma Investments
New York
|
-$2.07M |
| 5 |
IHAM
Integral Health Asset Management
New York
|
-$2.05M |